Abstract:Background and aims: HBV-specific T-cell receptor (HBV-TCR) engineered T cells have the potential for treating HCC relapses after liver transplantation, but their efficacy can be hampered by the concomitant immunosuppressive treatment required to prevent graft rejection. Our aim is to molecularly engineer TCR-T cells that could retain their polyfunctionality in such patients while minimizing the associated risk of organ rejection. Approach and results: We first analyzed how immunosuppressive drugs can interfere with the in vivo function of TCR-T cells in liver transplanted patients with HBV-HCC recurrence receiving HBV-TCR T cells and in vitro in the presence of clinically relevant concentrations of immunosuppressive tacrolimus (TAC) and mycophenolate mofetil (MMF). Immunosuppressive Drug Resistant Armored TCR-T cells of desired specificity (HBV or Epstein-Barr virus) were then engineered by concomitantly electroporating mRNA encoding specific TCRs and mutated variants of calcineurin B (CnB) and inosine-5'-monophosphate dehydrogenase (IMPDH), and their function was assessed through intracellular cytokine staining and cytotoxicity assays in the presence of TAC and MMF. Liver transplanted HBV-HCC patients receiving different immunosuppressant drugs exhibited varying levels of activated (CD39+ Ki67+ ) peripheral blood mononuclear cells after HBV-TCR T-cell infusions that positively correlate with clinical efficacy. In vitro experiments with TAC and MMF showed a potent inhibition of TCR-T cell polyfunctionality. This inhibition can be effectively negated by the transient overexpression of mutated variants of CnB and IMPDH. Importantly, the resistance only lasted for 3-5 days, after which sensitivity was restored. Conclusions: We engineered TCR-T cells of desired specificities that transiently escape the immunosuppressive effects of TAC and MMF. This finding has important clinical applications for the treatment of HBV-HCC relapses and other pathologies occurring in organ transplanted patients.

Possibility of Adoptive Immunotherapy With Peripheral Blood-derived CD3−CD56+ and CD3+CD56+ Cells for Inducing Antihepatocellular Carcinoma and Antihepatitis C Virus Activity

The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study

Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.

Expansion and Activation of Natural Killer Cells from PBMC for Immunotherapy of Hepatocellular Carcinoma

Microwave ablation and combined with adoptive immunotherapy for hepatocellular carcinoma

Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.

Study on Expansion of CD56+ Cytotoxic Lymphocytes from Human Umbilical Cord Blood

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Improvement of the Cytotoxic T Lymphocyte Response Against Hepatocellular Carcinoma by Transduction of Cancer Cells with an Adeno-Associated Virus Carrying the Interferon-Γ Gene.

Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

[Autologous Adoptive Immunotherapy Without Destruction of Infected Cells During the Treatment of Chronic Hepatitis B].

Minimally Invasive Treatment Combined With Cytokine-Induced Killer Cells Therapy Lower The Short-Term Recurrence Rates Of Hepatocellular Carcinomas

Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood

Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients

Targeted immune cell therapy for hepatocellular carcinoma using expanded liver mononuclear cell-derived natural killer cells

Preparation And Application Of Anti-Hbx/Anti-Cd3 Bispecific Monoclonal Antibody (Bsab) Retargeting Effector Cells For Lysis Of Human Hepatoma Xenografts In Nude Mice

Ex-vivo expansion of patient-derived PBMCs preferentially results in effector memory T-cell proliferation with restored autologous efficiency in HBV-HCC

Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Hbcag18-27 Epitope Fused To Hiv-Tat(49-57) Adjuvanted With Cpg Odn Induces Immunotherapeutic Effects In Transgenic Mice